Metabolic adaptations under high glucose enhance KRAS and lipid synthesis inhibitor efficacy in pancreatic cancer (AACRPanCa 2026) - Oct 15, 2026 - Abstract #B048; "The majority of PDAC cases do not display any symptoms and are diagnosed in the late stage, where Chemotherapies like gemcitabine or FOLFIRINOX offer limited benefits...To assess therapeutic potential, we treated PDAC cell lines with KRAS G12D inhibitor (MRTX1133) and FASN inhibitor TVB-2023 under low- and high-glucose conditions...In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026; 86(18_Suppl_2):Abstract nr B048."
Clinical • Diabetes • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • DOT1L • KRAS • SCD
|
|
GOUTAM Dey; Mehrdad Zarei; Priyashree Sunita; Sami Abul-Khoudoud; Faith Nakazzi; Hallie Graor; Jordan M. Winter
|